X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of TAK-935 (soticlestat), being developed by Takeda in two Phase 3 trials for Lennox-Gastaut syndrome and Dravet syndrome.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 18, 2023
Details:
The collaboration will advance clinical development of GV101, which is currently in a Phase 1 trial, along with other selective, small-molecule compounds from a library of ROCK2 inhibitors, that may penetrate the blood-brain barrier.
Lead Product(s): GV101
Therapeutic Area: Neurology Product Name: GV101
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Graviton Bioscience
Deal Size: $10.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration May 01, 2023
Details:
OV329 is a next-generation GABA-aminotransferase inhibitor being developed for the treatment of rare and treatment-resistant forms of epilepsy and seizures, such as seizures associated with tuberous sclerosis complex, infantile spasms, and conditions with focal onset seizures.
Lead Product(s): OV329
Therapeutic Area: Neurology Product Name: OV329
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
OV329,, a next-generation GABA-aminotransferase (GABA-AT) inhibitor demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures.
Lead Product(s): OV329
Therapeutic Area: Neurology Product Name: OV329
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
The company seeks to optimize and accelerate development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions such as OV350, could become a powerful weapon for clinicians seeking to treat a potential underlying cause of epilepsies.
Lead Product(s): OV350
Therapeutic Area: Neurology Product Name: OV350
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: $215.5 million Upfront Cash: $12.5 million
Deal Type: Collaboration January 03, 2022
Details:
Takeda Pharmaceutical secured global rights from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $856.0 million Upfront Cash: $196.0 million
Deal Type: Termination March 30, 2021
Details:
The primary endpoint of the NEPTUNE study was not achieved. Patients given OV101 showed a 0.7 point improvement in CGI-I-AS over baseline while placebo also showed a 0.8 point improvement in CGI-I-AS.
Lead Product(s): Gaboxadol
Therapeutic Area: Genetic Disease Product Name: OV101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS study).
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: OV935
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time .
Lead Product(s): Soticlestat
Therapeutic Area: Genetic Disease Product Name: TAK-935
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo in the combined Dravet syndrome and Lennox-Gastaut syndrome study population.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
